Drug-Eluting Technology Revolutionizes US Market for Coronary Stents
According to a newly published report by Millennium Research Group (MRG), in 2005, DES sales comprised over 90% of the $3 billion US coronary stent market. Driven by rapid penetration, growing patient populations, and improved technology and availability, US DES revenue should surpass $4.5 billion by 2009.
(PRWEB) July 29, 2005 -— The US coronary stent market was forever changed in
April 2003 with the introduction of Cordis’ Cypher sirolimus-eluting stent. By
allowing physicians to treat multi-vessel and more complex single-vessel cases,
drug-eluting stents (DES), including Cypher and Boston Scientific’s Taxus, have
precipitated increases in both the average number of stents placed per procedure
and the eligible US patient population. According to a newly published report by
Millennium Research Group (MRG), in 2005, DES sales comprised over 90% of the $3
billion US coronary stent market. Driven by rapid penetration, growing patient
populations, and improved technology and availability, US DES revenue should
surpass $4.5 billion by 2009.
In July 2004, the FDA issued a Class I
recall for Boston Scientific’s industry-leading paclitaxel-eluting Taxus stent
due to a design flaw involving balloon deflation. Over the course of the recall
period, Cordis was able to cannibalize a portion of Boston Scientific’s market
share, effectively repositioning its sirolimus-eluting Cypher as a leading-edge
DES. In spite of the market opportunity presented by the Taxus recall, Cordis
was unable to overtake Boston Scientific as the US DES market leader due to
problems with Cypher availability.
MRG’s US Markets for Coronary Stents
2005 examines the impact of both bare-metal and drug-eluting coronary stents on
the US market for interventional cardiology (IC). As part of MRG’s recently
released Marketfocus report series, the report offers unparalleled market
coverage of stents, including product analyses by brand, quarter, company,
delivery platform, and diameter. In-depth competitive analysis of all major
manufacturers, including Abbott Vascular (ABT), Boston Scientific (BSX), Cordis
(JNJ), Guidant (GDT), and Medtronic (MDT), provides further insight into
company-specific strategic marketing and business development
initiatives.
In addition to coronary stents, MRG’s 2005 Marketfocus
series offers US and European brand- and quarter-level coverage of PTCA balloons
and accessory devices, and US coverage of plaque modification. MRG has also
relaunched its Global Interventional Cardiology series, which features in-depth
analysis of IC-related markets in the US, with forthcoming coverage of Europe,
Japan, Latin America, and Asia Pacific.
A leading source of competitive
intelligence, MRG is now the largest provider of medical device market research
in the world. Located in Toronto, Canada, MRG covers global markets and has
pioneered reporting of numerous emerging products.
Contact
Information:
Derrick Navarro
Millennium Research Group Inc
+1 (416)
364-7776 ext. 133
www.mrg.net ;
Canossa
Chan
Millennium Research Group Inc
+1 (416) 364-7776 ext. 129
www.mrg.net
# #
#
Source : http://www.prweb.com/releases/2005/7/prweb266353.htm